title: Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.
abstract: We report a generalized skin eruption in a young man being treated with natalizumab, a new drug used in patients with multiple sclerosis.
authors.forename: Marisa C
authors.initials: MC
authors.lastname: André
authors.forename: David
authors.initials: D
authors.lastname: Pacheco
authors.forename: Joana
authors.initials: J
authors.lastname: Antunes
authors.forename: Raquel
authors.initials: R
authors.lastname: Silva
authors.forename: Paulo
authors.initials: P
authors.lastname: Filipe
authors.forename: L M
authors.initials: LM
authors.lastname: Soares de Almeida
mesh_terms: D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001569:Benzodiazepines / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D003009:Clorazepate Dipotassium / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004802:Eosinophilia / Q000097:blood / Q000473:pathology; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D008099:Liver / Q000201:enzymology; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000097:blood / Q000473:pathology
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D010455:Peptides; D011799:Quinazolines; D001569:Benzodiazepines; D000639:Amitriptyline; D002220:Carbamazepine; D000068717:Glatiramer Acetate; D003009:Clorazepate Dipotassium; D016899:Interferon-beta; C047638:alfuzosin; C014262:mexazolam; D000068556:Interferon beta-1a